Pfizer Brings Frequent Heartburn Relief Over-the-Counter with New Nexium 24HR
Pfizer Inc. has announced the introduction in the US of over-the-counter (OTC) Nexium 24HR, making The Purple Pill available for the treatment of frequent heartburn (two or more days a week) in adults (18 years and older). Heartburn affects more than 60 million men and women in the US at least once a month with 15 million Americans suffering from it daily.[1]
Pfizer acquired exclusive global OTC rights to NEXIUM, one of the largest selling prescription brands in the US, from AstraZeneca in August 2012. Nexium 24HR was approved by FDA on 28 March, and received 3-year market exclusivity. Switching medicines from prescription to non-prescription status improves consumer access to affordable healthcare options, empowers people to take charge of their health, and is an important strategy for Pfizer. The launch of Nexium 24HR makes Pfizer a leading player in all four of the largest OTC categories — pain management, dietary supplements, respiratory and, now, digestive.
“The addition of Nexium 24HR to our portfolio enhances our ability to help consumers better manage their health,” said Paul Sturman, President and General Manager, Pfizer Consumer Healthcare. “Nexium 24HR creates a new option for treating frequent heartburn with the confidence of a brand that consumers and healthcare providers know and trust. The OTC availability of Nexium 24HR in the U.S. marks the first step in our efforts to build a strong, global position in digestive health with this powerful brand.”
“Switching a brand with this kind of loyalty and equity is a tremendous business opportunity, and we have a critical responsibility to our partners, to our retail customers, to healthcare providers and most importantly, to consumers,” said T.J. Higgins, North American President, Pfizer Consumer Healthcare. “Nexium 24HR protects people from frequent heartburn, and also from the fear and hesitation that heartburn causes.”
Nexium 24HR works differently than other OTC medications for heartburn such as antacids and histamine blockers. Specifically, Nexium 24HR is a proton pump inhibitor (PPI), which means it stops acid production at the source, by blocking the pumps that release acid into the stomach. In fact, PPIs like Nexium 24HR are the only FDA-approved medications for over-the-counter treatment of frequent heartburn.
“I, along with many of my colleagues, have come to trust The Purple Pill as the number one prescribed acid blocker brand,” said David A. Johnson, MD, MACG, FASGE, Professor of Medicine and Chief of Gastroenterology Eastern VA Medical School Norfolk VA. “The availability of Nexium 24HR represents an important development in access to the medication at a time when people are in need of a short term course of therapy for effective self-care solutions. And with 15 million Americans suffering from heartburn daily[1], making NEXIUM available without prescription helps to fill a crucially important unmet need.”
Reference
[1] Smoking and Your Digestive System. 1999. National Digestive Diseases Information Clearinghouse. NIH Publication No.99-949.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance